New drug combo aims to outperform standard therapy for advanced colorectal cancer

NCT ID NCT07676162

Not yet recruiting Disease control Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time

Summary

This phase 3 trial tests whether adding the experimental drug SHR-A1811 to standard chemotherapy and bevacizumab works better than standard therapy alone for people with advanced colorectal cancer who have not had prior treatment. About 300 participants will receive either the new combination or the standard regimen. The study measures how long the cancer stays under control and whether tumors shrink.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SHR-A1811
What this could lead to: If successful, this could offer a more effective first-line treatment option for people with advanced colorectal cancer, potentially slowing disease progression.
What could go wrong: This is an early-phase 3 trial, and the experimental drug may not prove more effective than standard therapy. Side effects from combining multiple drugs could be significant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED COLORECTAL ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal adenocarcinoma colorectal cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED COLORECTAL CANCER

Contacts and locations

Locations

Beijing cancer Hospital

Beijing, Beijing Municipality, 100142, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.